ORIC
ORIC Pharmaceuticals, Inc. NASDAQ Listed Apr 24, 2020$12.79
Pre-mkt
$12.95
+1.28%
Mkt Cap $1.3B
52w Low $7.23
72.2% of range
52w High $14.93
50d MA $12.46
200d MA $10.69
P/E (TTM)
—
EV/EBITDA
—
P/B
2.9x
Debt/Equity
0.0x
ROE
-33.7%
P/FCF
-9.8x
RSI (14)
43.40
ATR (14)
$0.59
Beta
1.36
50d MA
$12.46
200d MA
$10.69
Avg Volume
1.2M
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
240 East Grand Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | AMC | -0.36 | -0.38 | -5.8% | 10.60 | +0.4% | +27.1% | -4.0% | +0.0% | +4.4% | +0.9% | — |
| May 4, 2026 | AMC | -0.32 | -0.34 | -6.0% | 9.63 | -2.3% | -0.6% | -2.8% | -5.3% | +0.5% | +1.6% | — |
| Feb 23, 2026 | AMC | -0.34 | -0.30 | +11.8% | 11.71 | +3.2% | +14.6% | -0.1% | +0.7% | -0.4% | +3.2% | — |
| Nov 13, 2025 | AMC | -0.41 | -0.33 | +19.5% | 12.19 | +2.1% | +0.5% | -1.6% | -1.3% | -3.5% | +0.0% | — |
| Aug 12, 2025 | AMC | -0.46 | -0.47 | -2.2% | 9.52 | +0.4% | +3.3% | +1.0% | -2.7% | +2.5% | -3.0% | — |
| May 5, 2025 | AMC | -0.51 | -0.42 | +17.6% | 5.70 | +2.3% | -11.6% | -6.7% | +13.2% | -4.5% | +6.5% | — |
| Feb 18, 2025 | AMC | -0.52 | -0.51 | +1.9% | 7.85 | +9.2% | +1.1% | -5.9% | +2.8% | -1.6% | +6.9% | — |
| Nov 12, 2024 | AMC | -0.48 | -0.49 | -2.1% | 10.26 | -0.3% | +0.1% | -14.0% | -3.7% | +0.7% | +3.9% | — |
| Aug 12, 2024 | AMC | -0.42 | -0.45 | -7.1% | 8.28 | -0.2% | +6.8% | +11.7% | +9.7% | -14.1% | +8.6% | — |
| May 6, 2024 | AMC | -0.44 | -0.37 | +15.9% | 9.37 | +0.7% | +2.6% | -0.1% | -1.0% | -5.4% | -0.2% | — |
| Mar 11, 2024 | AMC | -0.49 | -0.49 | +0.0% | 14.99 | -2.4% | -4.5% | +6.4% | -1.4% | +0.5% | -2.8% | — |
| Nov 6, 2023 | AMC | -0.46 | -0.44 | +4.3% | 6.90 | -1.4% | -0.7% | -0.7% | -5.4% | -3.0% | -1.8% | — |
| Aug 10, 2023 | AMC | -0.58 | -0.50 | +13.8% | 7.93 | +7.9% | +11.0% | -9.1% | +9.1% | +5.8% | -7.9% | — |
| May 8, 2023 | AMC | -0.54 | -0.53 | +1.9% | 5.22 | -2.1% | -2.5% | +1.0% | +0.6% | -1.1% | +1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12 | Stifel | Reiterates | Buy | $14 | $7.82 | $7.94 | +1.5% | +5.8% | +1.6% | -1.1% | +3.9% | -1.6% |
| May 15 | Goldman | Upgrade | Neutral → Buy | $15 | $8.34 | $8.53 | +2.3% | -2.3% | -2.7% | +0.5% | +5.5% | +0.6% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.48 | $7.25 | -3.1% | +18.9% | +0.2% | -0.4% | +2.0% | +14.7% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $12.67 | $10.25 | -19.1% | -41.0% | +18.9% | +0.2% | -0.4% | +2.0% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.76 | $11.96 | +1.7% | +1.2% | +2.7% | -1.2% | -10.0% | +2.2% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.71 | $12.08 | +3.2% | +14.6% | -0.1% | +0.7% | -0.4% | +3.2% |
| Feb 24 | Wedbush | Maintains | Outperform → Outperform | — | $11.71 | $12.08 | +3.2% | +14.6% | -0.1% | +0.7% | -0.4% | +3.2% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $11.71 | $12.08 | +3.2% | +14.6% | -0.1% | +0.7% | -0.4% | +3.2% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $9.15 | $9.07 | -0.9% | +10.8% | +10.9% | +2.4% | +5.2% | -4.1% |
| Dec 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.00 | $12.37 | +12.5% | -4.4% | -3.6% | -1.4% | -3.1% | -3.2% |
| Dec 8 | Wedbush | Maintains | Outperform → Outperform | — | $11.00 | $12.37 | +12.5% | -4.4% | -3.6% | -1.4% | -3.1% | -3.2% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $12.06 | $11.93 | -1.1% | -1.3% | -3.5% | +0.0% | +1.2% | +1.5% |
| Nov 17 | Citigroup | Maintains | Buy → Buy | — | $12.25 | $12.29 | +0.3% | -1.6% | -1.3% | -3.5% | +0.0% | +1.2% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.19 | $12.44 | +2.1% | +0.5% | -1.6% | -1.3% | -3.5% | +0.0% |
| Nov 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.19 | $12.44 | +2.1% | +0.5% | -1.6% | -1.3% | -3.5% | +0.0% |
| Nov 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $12.19 | $12.44 | +2.1% | +0.5% | -1.6% | -1.3% | -3.5% | +0.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.83 | $9.55 | -2.8% | +1.0% | -2.7% | +2.5% | -3.0% | -0.9% |
| Aug 14 | JP Morgan | Maintains | Overweight → Overweight | — | $9.83 | $9.55 | -2.8% | +1.0% | -2.7% | +2.5% | -3.0% | -0.9% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $9.52 | $9.56 | +0.4% | +3.3% | +1.0% | -2.7% | +2.5% | -3.0% |
| May 19 | JP Morgan | Maintains | Overweight → Overweight | — | $4.73 | $4.67 | -1.3% | +8.7% | +10.3% | +3.5% | +1.4% | +6.7% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.32 | $5.34 | +0.4% | -4.5% | +6.5% | -1.8% | -8.3% | -2.7% |
| May 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.70 | $5.83 | +2.3% | -11.6% | -6.7% | +13.2% | -4.5% | +6.5% |
| May 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.70 | $5.83 | +2.3% | -11.6% | -6.7% | +13.2% | -4.5% | +6.5% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.67 | $5.64 | -0.5% | +0.5% | -11.6% | -6.7% | +13.2% | -4.5% |
| Feb 26 | Guggenheim | Maintains | Buy → Buy | — | $8.08 | $8.50 | +5.2% | +2.7% | -5.5% | +2.4% | -4.9% | +0.3% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $8.08 | $8.50 | +5.2% | +2.7% | -5.5% | +2.4% | -4.9% | +0.3% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.08 | $8.50 | +5.2% | +2.7% | -5.5% | +2.4% | -4.9% | +0.3% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.68 | $7.69 | +0.1% | -1.6% | +6.9% | +2.7% | -5.5% | +2.4% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.69 | +2.9% | +2.8% | -1.6% | +6.9% | +2.7% | -5.5% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.23 | $11.72 | +4.4% | -12.3% | -4.1% | -12.5% | +1.1% | -6.1% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $12.25 | $12.31 | +0.5% | -8.3% | -12.3% | -4.1% | -12.5% | +1.1% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $12.39 | $12.67 | +2.3% | +1.2% | -2.3% | -8.3% | -12.3% | -4.1% |
| Jan 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.60 | $8.92 | +3.7% | +15.2% | +9.7% | -7.6% | -4.6% | +4.4% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.96 | $8.71 | +9.4% | +8.0% | +15.2% | +9.7% | -7.6% | -4.6% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.41 | $9.40 | -0.1% | +0.7% | +2.1% | +6.4% | -3.4% | +3.1% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.10 | $10.14 | +0.4% | +5.6% | +4.6% | +0.8% | -4.6% | +0.2% |
| Sep 10 | Wedbush | Maintains | Outperform → Outperform | — | $9.79 | $9.80 | +0.1% | +1.7% | -0.6% | -8.5% | +9.2% | +1.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.84 | $8.87 | +0.3% | +11.7% | +9.7% | -14.1% | +8.6% | -2.4% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $8.28 | $8.26 | -0.2% | +6.8% | +11.7% | +9.7% | -14.1% | +8.6% |
| Aug 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.28 | $8.26 | -0.2% | +6.8% | +11.7% | +9.7% | -14.1% | +8.6% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.99 | $11.63 | +5.8% | -7.0% | +0.0% | +0.0% | +4.6% | +5.3% |
| Jul 17 | Wedbush | Maintains | Outperform → Outperform | — | $10.99 | $11.63 | +5.8% | -7.0% | +0.0% | +0.0% | +4.6% | +5.3% |
| Jul 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.34 | $9.49 | +1.6% | -0.1% | +2.9% | +4.8% | +6.9% | +2.2% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $9.37 | $9.44 | +0.7% | +2.6% | -0.1% | -1.0% | -5.4% | -0.2% |
| Mar 27 | JP Morgan | Maintains | Overweight → Overweight | — | $13.46 | $13.54 | +0.6% | +0.1% | +2.1% | -6.0% | -5.9% | -6.4% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.36 | $15.16 | +5.6% | +1.6% | -4.7% | -3.2% | +0.0% | +0.1% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $14.99 | $14.63 | -2.4% | -4.5% | +6.4% | -1.4% | +0.5% | -2.8% |
| Mar 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.99 | $14.63 | -2.4% | -4.5% | +6.4% | -1.4% | +0.5% | -2.8% |
| Mar 12 | Baird | Maintains | Outperform → Outperform | — | $14.99 | $14.63 | -2.4% | -4.5% | +6.4% | -1.4% | +0.5% | -2.8% |
| Mar 1 | Wedbush | Maintains | Outperform → Outperform | — | $12.74 | $13.57 | +6.5% | +15.1% | +2.0% | +3.5% | +3.5% | -0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | Piscitelli Dominic | Chief Financial Officer | Sell | 77,000 | $13.69 | $1.1M | 69,828 | -1.89% | +0.94% |
| Jul 24, 2026 | Heyman Richard A. | — | Sell | 6,100 | $12.02 | $73K | 206,672 | -5.29% | +27.08% |
| Jul 24, 2026 | Heyman Richard A. | — | Sell | 7,000 | $12.02 | $84K | 38,300 | -5.29% | +27.08% |
| Jul 6, 2026 | Heyman Richard A. | — | Sell | 300 | $12.00 | $4K | 212,772 | +0.37% | +5.59% |
8-K
Unknown — 8-K Filing
ORIC is restating standard forward-looking statement disclaimers in an 8-K, suggesting material developments that require disclosure but no immediate operational changes warrant investor concern absent additional specifics.
Mar 31
8-K
Oric Pharmaceuticals, Inc. -- 8-K Filing
Oric Pharmaceuticals filed a prospectus supplement indicating preparation for a future securities offering, though no immediate sale has occurred or been announced.
Feb 23
8-K
Oric Pharmaceuticals, Inc. -- 8-K Filing
Oric Pharmaceuticals reported positive 2025 clinical data for lead candidates rinzimetostat in prostate cancer and enozertinib in lung cancer, potentially supporting its oncology pipeline advancement.
Feb 23
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 6,823,973 | $74M | New | Jun 2026 |
| 2 | Pfizer Inc | 4,780,401 | $58M | Reduced | Mar 2026 |
| 3 | Citadel Advisors Llc | 5,190,598 | $56M | Added | Jun 2026 |
| 4 | Viking Global Investors Lp | 5,126,762 | $56M | Reduced | Jun 2026 |
| 5 | Vr Adviser, Llc | 5,676,230 | $46M | Reduced | Dec 2025 |
| 6 | Column Group Llc | 3,540,777 | $45M | New | Mar 2026 |
| 7 | Vanguard Capital Management Llc | 3,951,169 | $43M | Added | Jun 2026 |
| 8 | Alkeon Capital Management Llc | 3,739,096 | $40M | Reduced | Jun 2026 |
| 9 | Siren, L.l.c. | 2,998,192 | $32M | New | Jun 2026 |
| 10 | Fmr Llc | 2,434,080 | $31M | Reduced | Mar 2026 |
| 11 | Vivo Capital, Llc | 1,848,786 | $23M | New | Mar 2026 |
| 12 | Mpm Bioimpact Llc | 1,803,945 | $23M | — | Mar 2026 |
| 13 | Morgan Stanley | 2,388,146 | $20M | Added | Dec 2025 |
| 14 | Franklin Resources Inc | 1,452,835 | $18M | Added | Mar 2026 |
| 15 | D. E. Shaw & Co., Inc. | 1,580,216 | $17M | Added | Jun 2026 |
| 16 | Woodline Partners Lp | 1,247,515 | $16M | Added | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 1,043,159 | $13M | Added | Mar 2026 |
| 18 | Defilade Capital Management, L.p. | 1,047,690 | $11M | New | Jun 2026 |
| 19 | Qube Research & Technologies Ltd | 859,491 | $11M | Reduced | Mar 2026 |
| 20 | Silverarc Capital Management, Llc | 1,116,604 | $9M | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.32B
Enterprise Value
$845.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.28x
P/B
2.92x
P/S
—
P/FCF
-9.84x
EV/EBITDA
—
Shares Out
87.8M
Financials (TTM)
Revenue
$0
Net Income
-$140.4M
EBITDA
-$143.0M
Free Cash Flow
-$114.1M
Op Cash Flow
-$113.4M
EPS Basic
$-1.47
EPS Diluted
$-1.35
EPS Forward
$-1.40
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$411.0M
Total Liab.
$26.6M
Total Equity
$384.4M
Cash
$281.5M
LT Debt
$4.1M
Book Value/Sh
$4.38
Debt/Equity
0.03x
Current Ratio
14.13
Quick Ratio
14.13
Returns & Growth
ROE
-33.7%
ROA
-31.7%
ROIC
-36.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+19.7%
Price Returns
2W
+0.4%
1M
-12.7%
3M
+43.2%
6M
+15.2%
12M
+21.1%
Technicals
52W High
$14.93
52W Low
$7.23
50d MA
$12.46
200d MA
$10.69
RSI (14)
43.40
ATR (14)
$0.59
Beta
1.36
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.75
High
$25.00
Low
$15.00
Median
$23.50
Data updated apr 26, 2026 5:51pm
· Source: financialmodelingprep.com